Form 4: RA Capital Acquires 3.53 Million Shares of Acrivon Therapeutics, Inc. (ACRV)

RA Capital Management, L.P. and affiliated entities acquired 3,530,000 shares of Acrivon Therapeutics at $8.50 per share, increasing their total holdings.

Summary

• RA Capital Management, L.P., along with related entities, filed a Form 4 disclosing changes in beneficial ownership of Acrivon Therapeutics, Inc. (ACRV) stock.
• On April 11, 2024, RA Capital acquired 3,530,000 shares of ACRV common stock at a price of $8.50 per share.
• Following this transaction, RA Capital Healthcare Fund, L.P. directly holds 7,914,206 shares.
• RA Capital Nexus Fund II, L.P. directly holds 426,302 shares.
• RA Capital Management, L.P., as the investment manager for both funds, along with its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership except to the extent of their pecuniary interest.
• Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a transaction. The increased stake could be interpreted as a positive signal, but the filing itself is simply a factual report.

Positives

• RA Capital's increased investment in Acrivon Therapeutics could be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The filing itself doesn't present any immediate risks, but investors should always consider the potential risks associated with any investment, including Acrivon Therapeutics.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and significant shareholders, providing transparency to the market.

Stakeholder Impact

• The increased stake by RA Capital could positively influence shareholder confidence.
• The transaction could potentially impact the stock price of Acrivon Therapeutics.

Key Dates